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INTRODUCTION
Graft-versus-host disease (GVHD) is the main compli-
cation of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) [1-5]. The pathophysiology of acute GVHD
includes 3 sequential phases [6,7]. In the first phase, the
conditioning regimen damages and activates host tissues.
Activated host cells secrete several cytokines and growth
factors, leading to increased expression of adhesion and cell
surface recognition molecules by host cells and thereby
enhancing the recognition of host minor or major histo-
compatibility antigens by mature donor T-cells. Antigen
presentation, as well as activation, proliferation, and differ-
entiation of donor T-cells, occurs in the second phase.
Finally, in the third phase, activated T-cells, but also natural
killer cells and tumor necrosis factor α, induce organ dam-
age and the clinical manifestations of GVHD [6,7]. The
most efficient method for prevention of GVHD is T-cell
depletion (TCD) of the graft [4,8-10]. However, this
process usually leads to an increased risk of relapse due to
the loss of the donor T-cell–mediated graft-versus-
leukemia (GVL) effect [4,8-11]. More recently, donor
alloreactivity against host tumor cells has been recognized
as a major factor of success in allo-HSCT [11-13]. This
GVL effect is so potent that some relapses after allo-HSCT
can be efficiently (70% long-term complete remissions
[CRs] in chronic myeloid leukemia [CML]) treated with
donor lymphocyte infusions (DLIs) [14-22]. However,
although DLI permits the achievement of CR in the major-
ity of CML patients, results in treatment of acute leukemia
or high-grade lymphoma patients are more disappointing,
probably because of the high proliferative capacity of these
tumor cells [14-16,21]. Because DLIs are particularly effec-
tive in inducing CRs if the infusions are performed in early
relapse, it may be more efﬁcient to give DLI before relapse
at a time when minimal residual disease is still present
[14,15,23,24]. Several investigators have studied a strategy
combining TCD of the graft followed by preemptive DLI
[25-32]. The aim of these approaches is to administer
donor lymphocytes after the cytokine storm [7] and after
the patient has recovered from conditioning-regimen–
related toxicities, thus diminishing the risk of acute GVHD
while preserving the GVL effect.
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ABSTRACT
GVHD is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT). GVHD is
due to donor lymphocytes that are cotransplanted with donor stem cells. These donor lymphocytes are primed by
histocompatibility differences between donors and recipients and activated by a cytokine storm caused by the condi-
tioning regimen. The most efficient method for prevention of GVHD consists of T-cell depletion (TCD) of the
graft. However, TCD usually leads to an increased risk of leukemia relapse because of the loss of the graft-versus-
leukemia (GVL) effect. Several groups have studied the feasibility of preemptive donor lymphocyte infusion (DLI)
to lessen the impact of TCD on leukemia relapse. Preemptive DLI is given several weeks to months after the trans-
plantation, ie, after the cytokine storm and after the patient has recovered from conditioning-regimen–related toxic-
ities. After briefly discussing various techniques of TCD of the graft and the efficacy of DLI, this article reviews the
first clinical studies evaluating a strategy of TCD of the graft followed by preemptive DLI.
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TCD OF THE GRAFT
Since 1981, hundreds of T-cell–depleted transplantations
have been performed using various methods of TCD [4].
These trials resulted in low incidence of acute and chronic
GVHD and reduced transplantation-related mortality but
also increased incidence of graft rejection, delayed immune
reconstitution, and posttransplantation lymphoproliferative
disorders and increased rates of leukemic relapse, particu-
larly for CML patients [4,8,10,33].
The initial methods of TCD were based on negative
selection techniques using physical separation (soybean lectin
agglutination, counterﬂow elutriation, and albumin-gradient
fractionation) or antibody-based purging (complement-
mediated lysis, immunotoxins, and immunomagnetic beads)
[4]. In the 1990s, CD34+ cell selection techniques were
developed [34-36]. These techniques permitted the positive
selection of hematopoietic stem cells and progenitors,
thereby reducing the number of T-cells infused by 3 to
4 logs (Figure 1) [37].
Although both GVHD and GVL reactions are initiated
by donor T-cells from the graft, there is evidence that dif-
ferent subsets of T-lymphocytes may be involved in these
2 processes and that it may be possible to separate the GVL
effect from GVHD (Table 1 and Figure 2). The Houston
group first showed that CD8 depletion combined with
cyclosporine prophylaxis could reduce the incidence and
severity of acute GVHD without compromising GVL activ-
ity [38,39]. This group reported results of a double-blind
randomized trial showing that patients included in the
CD8-depletion arm experienced signiﬁcantly less grades II
through IV acute GVHD than patients included in the con-
trol arm (20% versus 80%, P < .004), with a relapse rate
(10.5%) similar in the 2 groups [39].
Instead of eliminating all T-cells, some investigators
developed techniques in which only alloreactive T-cells are
removed from the graft or in which donor T-cells are aner-
gized prior to transplantation. Using this approach, Guinan
et al. recently showed that anergization of donor cells by
cytotoxic T-lymphocyte (CTL)-associated molecule 4
(CTLA-4) immunoglobulin may reduce GVHD after HLA-
mismatched bone marrow transplantation (BMT) [40].
DONOR LYMPHOCYTE INFUSION
From the first evidence in 1990 that leukemic relapse
after HSCT may be efficiently treated with DLI [20,41],
DLI has become standard therapy to treat relapses after
allo-HSCT [14-17,19,20,22,42-44]. Results of the 2 largest
multicenter studies showed that DLI can induce CR in
60% to 65% of CML cases and 15% to 38% of acute lym-
phocytic leukemia (ALL) and myelodysplasic syndrome
cases [14,15].
In patients with CML, the response rate is highest when
lymphocytes are infused in early cytogenetic relapse (79%)
and lowest in accelerated phase or blast crisis (19%) (Table 2)
[14,15,45]. It has been speculated that the better response of
CML may be explained by its low evolutivity (because the
time to response after DLI is often prolonged, the GVL
reaction may not have sufﬁcient time to develop in patients
with more rapidly progressive disease) and by the fact that
dendritic cells, the most potent antigen-presenting cells, are
part of the leukemic clone in CML and are capable of
inducing a strong T-cell response [18,45]. Moreover, several
observations suggest that BCR/ABL expression may
increase the susceptibility of leukemic cells to immune
cytolysis [46-48].
By contrast, the malignant cells in acute leukemia may
be less appropriate antigen-presenting cells and may lead to
the induction of anergy rather than antileukemic T-cell
response [18]. Some patients with ALL, chronic lympho-
cytic leukemia, Hodgkin’s disease, or lymphoma [49] as well
as multiple myeloma [50] have also responded to DLI or
discontinuation of immunosuppressive therapy [19,51-53].
Finally, the GVL effect mediated by DLI needs time: the
median time to achieve a cytogenetic remission was 85 days
(range, 28-241 days) for patients with CML (the time to
achieve molecular remission can be prolonged) and 34 days
(range, 16-99 days) for patients with AML.
The main complication of DLI is GVHD [14,15].
Acute GVHD occurs in approximately 60% of patients
(grade III or IV in approximately 20%) and is significantly
correlated with CR [14,15]. Chronic GVHD also occurs
in approximately 60% of patients (extensive in 30%) and
also correlates with response [14,15,54]. However, CR
may be observed in the absence of GVHD, indicating that
the GVL response may be independent of the clinical
development of GVHD [15,18,55,56]. It is possible to
reduce the risk of GVHD without impairing the GVL
effect by using CD8 depletion of DLI (Table 2) [55,57,58]
or by starting with a low dose of T-cells and increasing
the dose in a stepwise fashion in case of no response
[18,55,59-61].
Figure 1. Comparison of 2 methods of T-cell depletion of the graft:
CD34 selection (black bar) or CD8 depletion (white bar) [84].
Table 1. Observations Demonstrating that GVL Effects Can Occur in the
Absence of GVHD
1. AML patients who received identical-twin transplants have an
increased probability of relapse (relative risk, 2.58; P = .008) com-
pared with patients who received an HLA-identical sibling allograft
and did not develop GVHD [98].
2. Complete responses after DLI have been observed in the absence
of GVHD [14].
3. Complete responses after nonmyeloablative stem cell transplanta-
tion have been observed in the absence of GVHD [84].
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The other complication of DLI is marrow aplasia, which
occurs in about 20% of the patients and more frequently if
residual hematopoiesis is at least partially of recipient origin
[14,15]. Marrow aplasia resolves spontaneously in 50% of
patients and can be reverted in the majority of the other
patients by granulocyte colony-stimulating factor (G-CSF)
and/or donor hematopoietic stem cells [14,15]. The Seattle
group has compared results of G-CSF–mobilized and non-
mobilized DLI [62]. They observed no difference between
the 2 groups in the incidence of response, GVHD, or apla-
sia [62], showing that the pathogenesis of aplasia after DLI
is not restricted to the destruction of recipient hemato-
poietic cells but also involves failure of donor hematopoiesis
by undeﬁned mechanisms [62].
RATIONALE FOR TCD OF THE GRAFT FOLLOWED BY
PREEMPTIVE DLI
The pathophysiology of acute GVHD includes 3 sequen-
tial phases [6,7,63,64]. In the first phase, the conditioning
regimen damages host tissues. Activated host cells then
secrete inﬂammatory cytokines, leading to increased expres-
sion of adhesion and cell surface recognition molecules by
host cells and thereby enhancing the recognition of host
histocompatibility antigens by donor T-cells [6,7]. Interest-
ingly, the more intensive the conditioning regimen, the
more important is the cytokine storm and the higher the
risk of GVHD [65]. Thus, after TCD of the graft, delaying
the administration of donor lymphocytes after resolution of
tissue damage and the cytokine storm may not only delay
but circumvent acute GVHD.
A second factor that may confer resistance to GVHD in
the TCD setting may be the state of mixed chimerism [66-70].
In rodents, the initial persistence of host hematopoiesis has
been demonstrated to decrease the severity of GVHD [71].
Kolb et al. demonstrated in a dog model that DLI given
60 days after the transplantation converted mixed into com-
plete chimerism without any significant acute GVHD,
whereas dogs transfused on day 1 or on day 21 after the
transplantation developed lethal GVHD [72]. Similar results
were recently reported by Pelot et al. in a rodent model
[67]. Nonspeciﬁc suppressor cells, which recover ﬁrst from
host marrow in mixed chimeras, probably play an important
role in this phenomenon [67,72].
PREEMPTIVE DLI
The feasibility of TCD of the graft followed by pre-
emptive DLI was first demonstrated by the Jerusalem
group [25]. In a first series of 38 patients whose marrow
Figure 2. GVL effect in the absence of GVHD after NMSCT in a patient with non-Hodgkin’s lymphoma who relapsed after a prior autograft. A,
Positron emission tomographic (PET) scan with 18F-fluorodeoxyglucose on day 40 after NMSCT evidenced the persistence of an abdominal
adenopathy (arrow). The patient received CD8-depleted DLI on days 40 and 80 after NMSCT and did not experienced any GVHD. B, New PET
scan on day 100 demonstrated the achievement of CR.
Table 2. Response to DLI in CML patients
Kolb et al. [14] Collins et al. [15] Shimoni et al. [58]
Unmanipulated DLI Unmanipulated DLI CD8-Depleted DLI
Evaluable Complete Evaluable Complete Evaluable Complete
Patients, n Responses, % Patients, n Responses, % Patients, n Responses, %
Cytogenetic relapse 17 14 (82) 3 3 (100)
Hematologic relapse 50 39 (78) 34 25 (74)
15 13 (87)
Advanced phase 8 1 (13) 18 5 (28) 11 1 (9)
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was T-cell depleted with Campath 1M, patients received
weekly incremental doses of up to 107 T-cells/kg before
day 28, and the incidence of acute GVHD was 42% but
there was little chronic GVHD. In another group whose
marrow was T-cell depleted with varying doses of Cam-
path 1G, 43 patients received 3 incremental infusions of up
to 107 T-cells/kg either before day 28 (n = 7) or between
days 28 and 84 (n = 36). In this heterogeneous group, the
crude incidence rates of acute and chronic GVHD were
53% and 40%, respectively. Since these data were reported,
several other studies have also investigated the infusion of
T-cells a few weeks to a few months after T-cell–depleted
transplantation (Table 3) [25-32].
Conﬁrming the results of studies in dogs [72], a study by
Barrett et al. suggested the importance of the delay between
the transplantation and preemptive DLI [26]. In the Barrett
et al. study, 26 patients received 2 × 106 donor T-cells/kg on
day 30 and 5 × 107 cells/kg on day 45 (schedule 1) and
12 other patients received 1 × 107 donor T-cells/kg on day
30 (schedule 2). Thus, the total dose of lymphocytes was
higher but more delayed in schedule 1. The authors
observed a significantly higher incidence of grades II
through IV acute GVHD in schedule 2 patients than in
schedule 1 patients (100% versus 31.5%, respectively, P = .02)
[26] (Table 3). However, the study was not randomized and
no deﬁnitive conclusion can be drawn.
Schaap et al. compared 2 schedules of preemptive DLI
given at a median of 150 days after a partially T-cell–
depleted BMT [30]. Thirty-ﬁve patients without signiﬁcant
GVHD were scheduled to receive DLI (DLI group) and
47 patients who developed grade >1 acute GVHD or
chronic GVHD and did not receive DLI served as controls
(control group). In the DLI group, the first 6 patients
received 7 × 107 CD3+ cells/kg and 5 of these 6 patients
experienced acute GVHD (grade I, n = 2; grade III, n = 2;
grade IV, n = 4). The next 25 patients received 1 × 107 CD3+
cells/kg and only 8 of them developed acute GVHD (grade
I, n = 4; grade II, n = 4), suggesting that the dose of T-cells
in preemptive DLI inﬂuences the incidence and severity of
acute GVHD. However, because this was a single-arm
sequential study in which DLIs were given at widely varying
time points after transplantation, these results must be con-
ﬁrmed by a prospective randomized trial.
In the Schaap et al. study [30], the 3-year disease-free
survival rate was higher in the DLI group (77%) than in the
control group (45%) (P = .024) because of a lower 3-year
probability of relapse (18% versus 46%, P = .022), suggest-
ing that preemptive DLI may induce GVL effects. Con-
firming this finding, Alyea et al. achieved a higher 2-year
progression-free survival rate in a cohort of 14 myeloma
patients receiving CD8-depleted DLI after a CD6-depleted
BMT (65%) compared with a historical cohort of myeloma
patients who underwent CD6-depleted BMT without pre-
emptive DLI (41%) [29].
We have recently reported the results of a phase I-II
study evaluating the feasibility and toxicity of CD34-
selected allogeneic peripheral blood stem cell (PBSC) trans-
plantation followed by preemptive CD8-depleted DLI given
in incremental doses (2 × 106, 1 × 107, and 5 × 107 CD3+
cells/kg on days 60, 100, and 140, respectively, [patients 1-13]
or 1 × 107 and 5 × 107 CD3+ cells/kg on days 60 and 100,
respectively, [patients 14-24]). The 180-day incidence of
grades II through IV acute GVHD was 13% for HLA-
identical sibling transplantations and 38% for mismatched
transplantations [32].
Finally, the Boston group reported at the 2001 Ameri-
can Society of Hematology meeting the results of a random-
ized trial comparing the outcome of patients receiving
unmanipulated (n = 9) or CD8-depleted (n = 9) preemptive
DLI 5 to 6 months after they had undergone a T-cell–
depleted HSCT. Six of 9 patients receiving unmanipulated
DLI developed acute GVHD compared to 0 of 9 recipients
of CD8-depleted DLI (P = .009). The study also suggested
that CD8 depletion did not compromise antitumor activity or
conversion from mixed to complete donor chimerism [73].
PERSPECTIVES
T-Cell–Depleted Nonmyeloablative Stem Cell
Transplantation Followed by Preemptive DLI
Several studies have now shown that PBSC transplan-
tation after a reduced-intensity nonmyeloablative condi-
tioning regimen resulted in diminished toxicity compared
to conventional transplantations, sustained engraftment,
and long-term disease-free survival in many patients
[68,69,74-82]. However, the transplantation-related mor-
tality ranged from 10% to 20%, mainly because of GVHD
and its consequences [80,82,83]. To find a way to decrease
the incidence of GVHD after nonmyeloablative stem cell
transplantation (NMSCT), we recently investigated the
feasibility of NMSCT with CD8-depleted or CD34-
selected PBSC followed by preemptive CD8-depleted DLI
[84]. Twenty-one patients (median age, 51 years) with
high-risk malignancies and an HLA-identical sibling (n = 10)
or alternative donor (n = 11) who were ineligible for a con-
ventional transplantation were included. The nonmyeloab-
lative conditioning regimen consisted of 2 Gy total body
irradiation (TBI) alone (n = 7), 2 Gy TBI and 90 mg/m2
fludarabine (n = 9, previously untreated patients), or
3 g/m2 cyclophosphamide and 90 mg/m2 ﬂudarabine (n = 5,
patients who had previously received ≥12 Gy TBI).
Patients 1 through 5 (controls) received unmanipulated
PBSC and DLI; patients 6 through 18, CD8-depleted
PBSC and DLI; and patients 19 through 21, CD34-
selected PBSC followed by CD8-depleted DLI. Post-
transplantation immunosuppression was carried out with
cyclosporine A and mycophenolate mofetil. Initial engraft-
ment was seen in all patients, but 2 CML patients (13%)
later had graft rejection. The actuarial 180-day incidence
of grades II through IV acute GVHD was 80% for
patients 1 through 5 versus 18% for patients 6 through 21
(P = .0005) (Figure 3A). The evolution of white blood cell
chimerism is shown in Figure 3B.
REPLACING DLI BY SPECIFIC CTLS
Another method for separating the GVL effect from
GVHD could consist of the infusion of specific CTLs
instead of DLI. Donor-derived CTLs have been successfully
used to restore immunity against cytomegalovirus [85] and
Epstein-Barr virus [86-88] after allo-HSCT. Remarkably,
neither signiﬁcant toxicity nor GVHD were observed with
Cellular Immunotherapy after HSCT
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this early posttransplantation cell immunotherapy. The infu-
sion of donor-derived speciﬁc CTLs against speciﬁc antigens
such as minor histocompatibility antigens (mHA) preferen-
tially expressed in the hematopoietic system [89,90], tumor-
specific antigens [91], or antigens overexpressed in tumor
cells (such as proteinase 3 [92,93] or WT-1) [94] all represent
promising methods of immune cell therapy. In the littermate
dog model, the Seattle team has shown that mHA-sensitized
DLI (contrary to unmanipulated DLI) can reverse mixed to
complete donor chimerism with a low incidence of GVHD
[95]. In humans, the Leiden group reported the achievement
of CR in a patient with accelerated-phase CML by treatment
with leukemia-reactive CTLs [96,97]. Other studies assess-
ing the adoptive infusion of mHA-specific donor-derived
CTLs to patients with posttransplantation leukemic relapse
are currently in progress [80].
CONCLUSION
Although several authors have demonstrated the feasi-
bility of TCD of the graft followed by preemptive DLI,
2 important questions remain unresolved: (1) Does this
approach decrease the incidence of GVHD? (2) Does this
approach improve disease-free survival? Prospective ran-
domized trials comparing transplantation of unmanipulated
PBSC to that of T-cell–depleted PBSC followed by preemp-
tive DLI are needed to answer these 2 important questions.
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